Macroeconomics: The Day Ahead – 8 February 2021

Written by Marc Ostwald, ADMISI’s Global Strategist & Chief Economist

  • Digesting Japan services survey, German Production, awaiting Taiwan Trade and Eurozone Sentix survey on quiet day for stats; BoE’s Bailey, ECB’s Lagarde & Fed’s Mester; Trump Senate impeachment trial

  • Week Ahead: busy week for UK data, subdued elsewhere: China and US inflation top schedule; OPEC, EIA and WASDE monthly reports; plenty of central bank speakers & corporate earnings; US quarterly refunding


A quiet start to the new week in statistical terms has little more than Japan’s mixed services survey (current conditions unsurprisingly poor, outlook recovering quite sharply) and as expected German Industrial Production to digest ahead of the spurious Eurozone Sentix Investor Confidence and Taiwan’s trade data. The central bank schedule is busier with BoE Bailey facing some tough questioning in parliament on the LCF failure, while Lagarde testifies on ECB’s Annual Report, while on the political front, the Trump impeachment trial gets under way in the Senate. Outside of these items, there is little else in scheduled event terms, with markets once again opting for a willful blindness to incoming pandemic related news, focusing on flaling infection rates and US stimulus package hopes, and ignoring the withdrawal of the AstraZeneca vaccine in South Africa following a study showing it to be much less effective against the local mutation/variant.


RECAP –  The Week Ahead – Preview: 

The new week has a busy schedule of data from the UK (Q4 advance GDP, the usual array of monthly activity indicators and BRC Retail Sales), but a modest one elsewhere, which features US and China inflation, German Trade and Industrial Production, and Japanese services survey and Wages. There are also plenty more major corporate earnings reports, the US quarterly Treasury refunding, as well as the Lunar New Year holidays in China and the rest of Asia, and the start of Carnival in Europe. The commodities space will be looking to the OPEC and IEA oil market reports, along with the WASDE and Malaysia Palm Oil monthly reports. Central bank speakers will again be plentiful, with a busy week for central bank policy meetings (mostly EM) expected to see Sweden’s Riksbank on hold, while in the EM space only Banco de Mexico is seen taking any policy action with a 25 bps cut to 4.0%. On the political front, the progress of the Biden’s US fiscal package will continue to be closely monitored, as will Draghi’s progress in forming a new Italian government, with the previously seemingly improbable, if not impossible spectre of support from both M5S and the League sending positive signals. The question is whether this is nominal support, or whether after decades of stasis in Italian politics, Draghi is finally able to bang political heads together and create some momentum for long overdue reforms. Otherwise it will be about vaccination progress (colossally uneven across the globe), and some also more encouraging news on falling infection rates, though still a very far cry from suggesting the war against the virus is being won.

Economic data remains little more than roadkill to markets that are dining out on central bank ‘largesse to excess’, and the wishful seeing and deep seated yearning for a vaccine driven economic recovery at the very latest in H2 2021, but the week’s inflation data from China and the US should still bear some scrutiny. In China CPI is expected to slip back to -0.2% y/y after December’s stronger than expected 0.1%, primarily due to base effects as CPI jumped up to and peaked at 5.4% (vs Dec 2019 4.5%). It would in fact have fallen a lot further were it not for current upward pressures in food prices due to a very cold winter and movement restrictions due to localized spike in infection rates (see chart attached), even if pork price pressures are starting to ease. China’s PPI on the other hand should at the margin be benefitting from base effects, but is expected to rise to 0.3% y/y from December’s -0.4%, which would be the highest reading since May 2019, and paced by broad based commodity price pressures, and will start to rise much more sharply in coming months due to adverse base effects (and not just in China, but through much of the world, as well as the rise in commodity prices (assuming these persist, as seems reasonable). As for the US, a 6.3% m/m rise in gasoline prices suggests some upside risks to an expected 0.3% m/m that would see the y/y rate edge up to 1.5% from 1.4%, while core CPI is seen up 0.2% m/m to push the y/y down to 1.5% from 1.6%; both obviously well below the Fed’s inflation target, for a tenth consecutive month in core terms. However underlying trends in goods and services are heavily divergent, as can be seen on the attached chart, with housing & shelter costs now heavily constraining services, while goods prices emerge from almost a decade of effectively flat lining. Central banks may be keen to look through all the noise in inflation data in coming months, but will find their forward rate and liquidity guidance severely challenged, if these trends persist into H2 2021, above if core CPI measures were to be elevated.

The other ongoing talking point will be the steepening in G7 yield curves, most notably in the US. While the latter is above all notable for rising long-term nominal (as opposed to real) yields, it is also due to short-dated yields being crushed by excess liquidity, and as noted last week, by the Treasury’s decision to halve the size of its Cash Balance at the Fed in Q1 (see charts).

To view the full report and to sign up for daily market commentary please email

The information within this publication has been compiled for general purposes only. Although every attempt has been made to ensure the accuracy of the information, ADM Investor Services International Limited (ADMISI) assumes no responsibility for any errors or omissions and will not update it. The views in this publication reflect solely those of the authors and not necessarily those of ADMISI or its affiliated institutions. This publication and information herein should not be considered investment advice nor an offer to sell or an invitation to invest in any products mentioned by ADMISI.

© 2021 ADM Investor Services International Limited.

Risk Warning: Investments in Equities, Contracts for Difference (CFDs) in any instrument, Futures, Options, Derivatives and Foreign Exchange can fluctuate in value. Investors should therefore be aware that they may not realise the initial amount invested and may incur additional liabilities. These investments may be subject to above average financial risk of loss. Investors should consider their financial circumstances, investment experience and if it is appropriate to invest. If necessary, seek independent financial advice.

ADM Investor Services International Limited, registered in England No. 2547805, is authorised and regulated by the Financial Conduct Authority [FRN 148474] and is a member of the London Stock Exchange. Registered office: 3rd Floor, The Minster Building, 21 Mincing Lane, London EC3R 7AG.                  

A subsidiary of Archer Daniels Midland Company.

© 2024 ADM Investor Services International Limited.

Futures and options trading involve significant risk of loss and may not be suitable for everyone.  Therefore, carefully consider whether such trading is suitable for you in light of your financial condition.  The information and comments contained herein is provided by ADMIS and in no way should be construed to be information provided by ADM.  The author of this report did not have a financial interest in any of the contracts discussed in this report at the time the report was prepared.  The information provided is designed to assist in your analysis and evaluation of the futures and options markets.  However, any decisions you may make to buy, sell or hold a futures or options position on such research are entirely your own and not in any way deemed to be endorsed by or attributed to ADMIS. Copyright ADM Investor Services, Inc.